According to Oncomine database DR1, EVI5, TMED5 and RPL5 are co-amplified also in brain [41–43], colon [44], lung cancer [45] and melanoma [46], indicating that amplification of 1p21-22 may be a recurrent alteration in several different types of cancers. Here, RPL5 is linked to lung carcinoma.